BOP2-FE: Bayesian optimal phase II design with futility and efficacy-stopping boundaries.

Area of Science:

• Clinical Trials
• Biostatistics
• Oncology Drug Development

Background:

• Single-arm phase II trials are crucial for evaluating anticancer agent effectiveness and guiding go/no-go decisions.
• Maintaining patient safety is paramount during these trials.
• Existing designs may lack flexibility in early stopping for efficacy or futility.

Purpose of the Study:

• To introduce a flexible Bayesian optimal phase II design with futility and efficacy stopping boundaries for single-arm clinical trials, named BOP2-FE.
• To evaluate the performance of the BOP2-FE design through simulation studies.
• To demonstrate the advantages of BOP2-FE over existing designs in terms of sample size and statistical power.

Main Methods:

• The study proposes the BOP2-FE design, a Bayesian approach for single-arm phase II trials.
• This design incorporates pre-specified futility and efficacy stopping boundaries for early trial termination.
• Simulation studies were conducted to compare BOP2-FE with other designs under various scenarios.

Main Results:

• The BOP2-FE design enables early stopping for efficacy when antitumor effects are significantly higher than the null hypothesis.
• Simulation results indicate that BOP2-FE strictly controls the type I error rate.
• The proposed design reduces the total sample size under the alternative hypothesis while maintaining or improving statistical power compared to existing methods.

Conclusions:

• The BOP2-FE design offers a flexible and statistically robust approach for phase II single-arm oncology trials.
• It effectively balances the need for early efficacy detection with patient safety and resource optimization.
• BOP2-FE provides a valuable alternative for optimizing clinical trial design in oncology drug development.